Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AMU0 | ISIN: GB00BYT1DJ19 | Ticker-Symbol: I2X2
Frankfurt
22.01.25
08:07 Uhr
25,000 Euro
0,000
0,00 %
1-Jahres-Chart
INTERMEDIATE CAPITAL GROUP PLC Chart 1 Jahr
5-Tage-Chart
INTERMEDIATE CAPITAL GROUP PLC 5-Tage-Chart
RealtimeGeldBriefZeit
26,60027,60014:54
GlobeNewswire (Europe)
43 Leser
Artikel bewerten:
(0)

Intermediate Capital Group plc: Q3 trading statement for the nine months ended 31 December 2024

Finanznachrichten News
ICG plc
22 January 2025
Q3 update for the nine months ended 31 December 2024

$22bn raised in the last twelve months
Highlights

  • Strong fundraising of $7.2bn in the quarter resulting in $22bn raised in the last twelve months, more than twice as much as raised in calendar 2023 and supporting long-term growth in client capital and management fees
  • Client commitments included $1.8bn to Strategic Equity and $1.8bn to Europe IX. Europe IX expected to be activated and fee-earning by March 2025
  • AUM of $107bn (+5.1% q-o-q1); fee-earning AUM of $71bn (+2.8% q-o-q1); AUM not yet earning fees of $20bn
  • Investment environment remains in line with recent quarters
  • Balance sheet investment portfolio during the quarter generated positive NIR in all asset classes and net cash realisations
  • AAA ESG rating awarded by MSCI for the fourth consecutive year, membership of the Dow Jones Sustainability Index (Europe) for the second consecutive year
  • Shareholder seminar on ICG Strategic Equity to be held online on 5 March 2025 at 5pm GMT. Register here
  • Sonia Baxendale joined the Board as a Non-Executive Director in January 20252
Unless otherwise stated the financial results discussed herein are on the basis of alternative performance measures (APM) basis; see full year results
1 On a constant currency basis; 2 As previously announced.

PERFORMANCE REVIEW

AUM
Growth1
31 December 2024Last three monthsYear-on-yearLast five years (CAGR)
AUM$107bn5.1%27.5%19.3%
Fee-earning AUM$71bn2.8%8.1%14.7%
1 On a constant currency basis
Note: historical AUM has not been updated to reflect AUM policy change effective March 2024. This does not impact fee-earning AUM
Business activity
$bn

Fundraising Deployment1 Realisations1,2
Q3 FY25LTM Q3 FY25LTM Q3 FY25LTM
Structured and Private Equity5.310.1 1.07.4 0.21.0
Private Debt0.26.6 1.23.3 1.74.4
Real Assets0.71.5 0.82.0 0.51.4
Credit1.03.6
Total7.221.8 3.012.7 2.46.8
1 Direct investment funds; 2 Realisations of fee-earning AUM

PERIOD IN REVIEW

AUM and FY25 fundraising

At 31 December 2024, AUM stood at $107bn and fee-earning AUM at $71bn. The bridge between AUM and fee-earning AUM is as follows:

$mStructured and Private EquityPrivate DebtReal AssetsCreditSeed investmentsTotal
Fee-earning AUM31,93214,3537,40117,451-71,137
AUM not yet earning fees4,44913,956751356-19,512
Fee-exempt AUM8,3651,3183,035--12,718
Balance sheet investment portfolio12,329148458(183)4523,204
AUM47,07529,77511,64517,624452106,571
1 Includes elimination of $634m (£507m) within Credit due to how the balance sheet investment portfolio accounts for and invests into CLO's managed by ICG and its affiliates

At 31 December 2024 we had $30bn of AUM available to deploy in new investments ("dry powder"), of which $20bn was not yet earning fees.

The stronger US Dollar at 31 December 2024 compared to 30 September 2024 impacted the US Dollar value of our non-US Dollar (predominantly Euro) funds. We receive management fees in the fund currency.

AUM

AUM ($m)Structured and Private EquityPrivate DebtReal AssetsCreditSeed investmentsTotal
At 1 October 2024 43,45331,90612,26618,106527106,258
Fundraising5,3501816801,029 7,240
Other additions81552193 385
Realisations(168)(848)(427)(852) (2,295)
Market and other movements(1,518)(1,612)(1,082)(688) (4,900)
Balance sheet movement(50)(7)(11)26(75)(117)
At 31 December 202447,07529,77511,64517,624452106,571
Change $m3,622(2,131)(621)(482)(75)313
Change %8%(7%)(5%)(3%)(14%)-%
Change % (constant exchange rate)13%(2%)2%2%(8%)5%

Fee-earning AUM

Fee-earning AUM ($m)Structured and Private EquityPrivate DebtReal AssetsCreditTotal
At 1 October 2024 31,18415,6857,73117,95772,557
Funds raised: fees on committed capital1,941-543-2,484
Deployment of funds: fees on invested capital521,1483091,0642,573
Total additions1,9931,1488521,0645,057
Realisations(159)(1,683)(529)(872)(3,243)
Net additions / (realisations)1,834(535)3231921,814
FX and other(1,086)(797)(653)(698)(3,234)
At 31 December 202431,93214,3537,40117,45171,137
Change $m748(1,332)(330)(506)(1,420)
Change %2%(9%)(4%)(3%)(2%)
Change % (constant exchange rate)7%(4%)2%2%3%

FY25 fundraising

At 31 December 2024, funds that were actively fundraising included Strategic Equity V; Europe Mid-Market II; Europe IX; Core Private Equity; European Infrastructure II; and various Real Estate strategies. We anticipate having final closes for Strategic Equity V and Europe Mid-Market II before the end of FY25, although the size and timing of such closes remains dependent on market conditions.

Balance sheet

  • The balance sheet investment portfolio generated positive NIR across all asset classes and net cash realisations during the quarter. We remain confident our balance sheet will continue to deliver in line with our guidance. At 31 December 2024 it was valued at £3,067m:
£m30 September 202431 December 2024
Structured and Private Equity1,7781,861
Private Debt116119
Real Assets350365
Credit319361
Seed investments394361
Balance sheet investment portfolio2,9573,067
  • At 31 December 2024 the Group had total available liquidity of £1.1bn (H1 FY25: £0.9bn)

FOREIGN EXCHANGE RATES

Average ratePeriod end
Q3 FY24Q3 FY2530 September 202431 December 2024
GBP:EUR1.15391.19921.20121.2086
GBP:USD1.25031.27171.33751.2516
EUR:USD1.08351.07401.11351.0356

COMPANY TIMETABLE

Shareholder seminar (online):
ICG Strategic Equity
5 March 2025, 5pm GMT
Register here
Full year results announcement21 May 2025

ENQUIRIES

Shareholders and debtholders / analysts:
Chris Hunt, Head of Corporate Development and Shareholder Relations, ICG+44(0)20 3545 2020
Media:
Clare Glynn, Head of Corporate Communications, ICG+44(0)79 3435 7794

This results statement may contain forward looking statements. These statements have been made by the Directors in good faith based on the information available to them up to the time of their approval of this report and should be treated with caution due to the inherent uncertainties, including both economic and business risk factors, underlying such forward looking information.

ABOUT ICG

ICG provides flexible capital solutions to help companies develop and grow. We are a global alternative asset manager with over 30 years' history, operating across four asset classes: Structured and Private Equity, Private Debt, Real Assets, and Credit.

We develop long-term relationships with our business partners to deliver value for shareholders, clients and employees. We are committed to being a net zero asset manager across our operations and relevant investments by 2040.

ICG is listed on the London Stock Exchange (ticker symbol: ICG). Further details are available at www.icgam.com.


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.